Physician profile
Rick Chadha
NPI 1992770598
$4,393.81
in general payments reported to CMS, 2019-2025
28 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $906 · 2020: $217 · 2021: $272 · 2022: $100 · 2023: $917 · 2024: $558 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,898.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,254.81 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $470.73 | 2019-2025 | Stelara, Tremfya |
| Madrigal Pharmaceuticals | $440.83 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $413.18 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $290.48 | 2019-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $249.27 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $237.96 | 2019-2025 | Entyvio, Eohilia |
| Janssen Scientific Affairs, LLC | $194.16 | 2023 | Stelara |
| Boston Scientific Corporation | $142.50 | 2019 | |
| Merck Sharp & Dohme LLC | $80.85 | 2019-2022 | |
| Allergan, INC. | $64.85 | 2019 | |
| Nestle Healthcare Nutrition INC. | $61.91 | 2023 | |
| Phathom Pharmaceuticals, INC. | $61.41 | 2024-2025 | Voquezna |
| Genzyme Corporation | $60.92 | 2025 | |
| Lilly USA, LLC | $58.90 | 2024-2025 | Omvoh |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $41.16 | 2025 | Vegzelma |
| Evoke Pharma, INC. | $34.80 | 2023-2024 | Gimoti |
| Ferring Pharmaceuticals INC. | $33.16 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.81 | 2025 | Dupixent |
| Braintree Laboratories, INC. | $32.15 | 2019-2022 | |
| Ardelyx, INC. | $30.84 | 2024 | Ibsrela |
| Medtronic, INC. | $22.76 | 2024 | Gi Genius |
| Astrazeneca Pharmaceuticals LP | $21.93 | 2019 | |
| Celgene Corporation | $18.63 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.48 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.61 | 2024 | |
| Novartis Pharmaceuticals Corporation | $12.72 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$41,211.71 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rick Chadha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.